Elicio Therapeutics Azioni (NASDAQ: ELTX)

Elicio Therapeutics (NASDAQ:ELTX) Azioni

Elicio Therapeutics

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.

Elicio Therapeutics Inc

Northfield Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFBK#NASDAQ">NFBK</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.18 by 5.56 percent. This is a 26.67 percent increase over earnings of $0.15 per share from the same period last year. The company reported quarterly sales of $31.79 million which missed the analyst consensus estimate of $32.01 million by 0.69 percent. This is a 14.01 percent increase over sales of $27.88 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

NFBK

Northfield Bancorp Q1 EPS $0.19 Beats $0.18 Estimate, Sales $31.79M Miss $32.01M Estimate

DA Davidson analyst Gil Luria maintains Pegasystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) with a Neutral and raises the price target from $70 to $90.

Price Target

Analyst Ratings

PEGA

DA Davidson Maintains Neutral on Pegasystems, Raises Price Target to $90

Editor's Note: This article has been deleted at the request of the company after the underlying press release was found to be prematurely issued and not intended for public distribution.

General

CPNG

Coupang Program Story (DELETED)

StorageVault Canada (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SVI#TSX">SVI</a>) reported quarterly losses of $(0.03) per share. This is a 58.33 percent increase over losses of $(0.07) per share from the same period last year. The company reported $76.27 million in sales this quarter. This is a 2.70 percent increase over sales of $74.27 million the same period last year.

TSX:SVI

StorageVault Canada Q1 EPS $(0.03) Up From $(0.07) YoY, Sales $76.27M Up From $74.27M YoY

<a href="https://noginc.com/sustainability/default.aspx">https://noginc.com/sustainability/default.aspx</a>

NOG Reveals 2024 ESG Report

Macquarie analyst Chad Beynon maintains Monarch Casino &amp; Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRI#NASDAQ">MCRI</a>) with a Neutral and maintains $92 price target.

MCRI

Macquarie Maintains Neutral on Monarch Casino & Resort, Maintains $92 Price Target

Precision Drilling (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PD#TSX">PD</a>) reported quarterly earnings of $2.20 per share which beat the analyst consensus estimate of $2.09 by 5.26 percent. This is a 13.04 percent decrease over earnings of $2.53 per share from the same period last year. The company reported quarterly sales of $496.33 million which missed the analyst consensus estimate of $499.91 million by 0.72 percent. This is a 5.96 percent decrease over sales of $527.79 million the same period last year.

TSX:PD

Precision Drilling Q1 EPS $2.20 Beats $2.09 Estimate, Sales $496.33M Miss $499.91M Estimate

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is still one of Wall Street&#8217;s most-watched names, but now it&#8217;s less about innovation and more about crash landings — figuratively speaking. 
With the stock off 33% year-to-date, investors are picking through the wreckage, trying to discern what comes next. A number of <a href="https://www.benzinga.com/etfs">ETFs with major Tesla exposure</a> have been in the hot seat lately, some expecting a bounce, others preparing for more bruises.
Simplify Volt TSLA Revolution ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TESL#NYSE">TESL</a>) is arguably the most Tesla-heavy of them all, with a 54% weightage. It actively manages Tesla volatility through options overlays — imagine a high-risk Tesla with a parachute. Whether that parachute deploys in time is anyone&#8217;s guess.
Nightview Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NITE#NYSE">NITE</a>) contains a Tesla weighting of 18.4%, ranking as one of the most exposed to Tesla of all the mainstream funds. For holders of this ETF, headlines on Tesla are more than mere news, these are portfolio-forming events.
Vanguard Consumer Discretionary ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VCR#NYSE">VCR</a>) isn&#8217;t far behind either, with Tesla contributing 13.3% to its portfolio.
As the stock plunges further and Wall Street analysts cut price targets in anticipation of every earnings season, these ETFs are traversing a rather Musk-ified market risk, one part fundamentals, one part drama.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44957724/tesla-stock-faces-demand-political-tariff-pressure-why-analysts-focus-on-multiple-generational-growth-drivers">Tesla Stock Faces Demand, Political, Tariff Pressure: Why Analysts Focus On &#8216;Multiple Generational Growth Drivers&#8217;</a>
<h1 class="wp-block-heading">Tariffs, Trouble &amp; Tesla&#8217;s Energy Mirage</h1>
Below the stock chart and into the details, Tesla&#8217;s most recent earnings report was a mixed bag. One welcome silver lining? The company&#8217;s energy and storage division, which reported $2.7 billion in revenue, up 67% from last year, with gross profit up a healthy 82%. But the celebration was short-lived.
<a href="https://www.benzinga.com/25/04/44942968/teslas-energy-business-carried-q1now-tariffs-could-kill-the-momentum-as-cfo-says-the-impact-will-be-outsized">CFO Vaibhav Taneja also identified a huge threat</a>: the <a href="https://www.benzinga.com/topic/tariffs">tariff headwinds</a> that endanger the segment. &#8220;The impact of tariffs on the energy business will be outsized since we source LFP battery cells from China,&#8221; he pointed out on the call.
Tesla&#8217;s alternative plan is to commission battery cell production in the country and search for outside-China suppliers. But Taneja conceded, &#8220;it will take time,&#8221; words not necessarily reassuring for investors eager to feed growth.
At the same time, Tesla&#8217;s brand-new <a href="https://in.benzinga.com/25/02/43519412/teslas-first-megafactory-outside-us-to-start-production-on-feb-11-report?_gl=1&#x2A;7umjf6&#x2A;_gcl_au&#x2A;OTE5OTY0NTM4LjE3NDM0MTQxMTE.&#x2A;_ga&#x2A;ZGVsZXRlZA..&#x2A;_ga_V7ZK73W7N0&#x2A;MTc0NTQzNTIyNy4xLjAuMTc0NTQzNTIyNy4wLjAuMA..">megafactory in Shanghai</a> — designed to turbocharge global energy storage manufacturing — has already hit turbulence. New tariffs have thrown a wrench into those overseas expansion plans just months after opening, potentially sidelining the company&#8217;s ambitious 50% growth projection for 2025.
And then there&#8217;s the &#8220;Elon&#8221; of all things. Musk&#8217;s polarizing political image, particularly his heightened profile in the Trump administration, has ignited vitriol — protests, boycotts, even crimes — against the brand. Sales suffered, analysts were doubtful and the company leadership&#8217;s priority seems, well, unfocused.
As Musk publicly attacks tariffs, ironically the same instrument ruining his own company&#8217;s drive into energy, one might have assumed his political stance would finally win out over criticism, and settle down to tidy up the perception mess around core customer segments.
<h1 class="wp-block-heading">What To Watch</h1>
ETF Tweaks: Will high-exposure ETFs rebalance or double down on Tesla? Monitor quarterly reshuffles and options activity.
Energy Segment Headwinds: Advancement on U.S.-based battery manufacturing and alternative suppliers will be paramount to keeping the energy segment afloat.
Geopolitical Shockwaves: Additional tariff ramp-ups or political noises surrounding China-U.S. trade could amplify risks for Tesla — and transmit through ETFs.
Elon&#8217;s Impact: Never underestimate the market-moving ability of a Musk tweet or political shift.
For investors, it&#8217;s a high-voltage waiting game. Whether Tesla recovers or ignites further volatility, one thing&#8217;s certain — the ETFs riding its fate will be anything but dull.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/04/44962489/vix-is-still-wild-but-not-for-long-3-volatility-etfs-to-grab-before-calm-returns">VIX Is Still Wild, But Not for Long: 3 Volatility ETFs To Grab Before Calm Returns</a></li>
</ul>
Photo: Courtesy Tesla Inc.

Specialty ETFs

Global

Trading Ideas

ETFs

NITE

TESL

TSLA

Select Sector SPDR-Consumer Discretionary

Tesla's Energy Division Shines, But ETF Risks Mount Amid Broader Challenges

<a href="https://www.youtube.com/watch?v=0lVi_OBmQd4">https://www.youtube.com/watch?v=0lVi_OBmQd4</a>

Politics

Economics

President Trump Says Over Next Two, Three Weeks Will Set Tariff For China; Says Will Have Big Tax Breaks

Precision Drilling (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PDS#NYSE">PDS</a>) reported quarterly earnings of $1.53 per share which missed the analyst consensus estimate of $1.57 by 2.55 percent. This is a 18.62 percent decrease over earnings of $1.88 per share from the same period last year. The company reported quarterly sales of $345.75 million which missed the analyst consensus estimate of $348.70 million by 0.84 percent. This is a 11.70 percent decrease over sales of $391.58 million the same period last year.

Precision Drilling Q1 EPS $1.53 Misses $1.57 Estimate, Sales $345.75M Miss $348.70M Estimate

Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) is looking for Q2 Adj EPS of $0.59-$0.65 vs $0.62 analyst estimate. sees sales of $1.450 billion-$1.530 billion vs $1.46 billion analyst estimate.

Guidance

Edwards Lifesciences Sees Q2 Adj EPS $0.59-$0.65 vs $0.62 Est; Sees Sales $1.450B-$1.530B vs $1.46B Est

President Trump Says Depends On China How Soon Tariffs Can Come Down

STEL

Stellar Bancorp Announces $65M Share Repurchase Program

ESSA Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESSA#NASDAQ">ESSA</a>) reported quarterly earnings of $0.29 per share. This is a 39.58 percent decrease over earnings of $0.48 per share from the same period last year. The company reported $16.23 million in sales this quarter. This is a 3.74 percent decrease over sales of $16.86 million the same period last year.

ESSA

ESSA Bancorp Q2 EPS $0.29 Down From $0.48 YoY, Sales $16.23M Down From $16.86M YoY

Northfield Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFBK#NASDAQ">NFBK</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.18 by 5.56 percent. This is a 26.67 percent increase over earnings of $0.15 per share from the same period last year.

Northfield Bancorp Q1 EPS $0.19 Beats $0.18 Estimate

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has outperformed the market over the past 15 years by 8.62% on an annualized basis producing an average annual return of 19.05%. Currently, UnitedHealth Group has a market capitalization of $389.54 billion. 
Buying $100 In UNH: If an investor had bought $100 of UNH stock 15 years ago, it would be worth $1,405.91 today based on a price of $427.96 for UNH at the time of writing.
<h3>UnitedHealth Group's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745443826_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning UnitedHealth Group Stock In The Last 15 Years

Alaska Air Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) is looking for Q2 Adj EPS of $1.15-$1.65 vs $2.54 analyst estimate..

Alaska Air Gr Sees Q2 Adj EPS $1.15-$1.65 vs $2.54 Est

Biotech

MLYS

Mineralys Therapeutics Reveals Publication Of Pivotal Phase 2 Advance-HTN Results In The New England Journal Of Medicine

Alaska Air Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) reported quarterly losses of $(0.77) per share which missed the analyst consensus estimate of $(0.74) by 4.05 percent. This is a 16.3 percent increase over losses of $(0.92) per share from the same period last year. The company reported quarterly sales of $3.14 billion which missed the analyst consensus estimate of $3.17 billion by 1.16 percent. This is a 40.55 percent increase over sales of $2.23 billion the same period last year.

Alaska Air Gr Q1 Adj. EPS $(0.77) Misses $(0.74) Estimate, Sales $3.14B Miss $3.17B Estimate

Marvell Technology, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) on Wednesday&nbsp;announced the successful interoperability of the&nbsp;Marvell Structera&nbsp;portfolio of Compute Express Link&nbsp;(CXL) devices&nbsp;with Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) EPYC CPUs and&nbsp;5th&nbsp;Gen Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44948063/marvell-announces-successful-interoperability-of-structera-cxl-portfolio-with-amd-epyc-cpu-and-5th" rel="noreferrer noopener">Intel Xeon platforms</a>.
The move marks Marvell&#8217;s progress towards an open and interoperable CXL ecosystem, which will address the growing demands for memory bandwidth and capacity in next-generation cloud data centers.
Marvell tapped AMD and Intel to extensively test Structera CXL products with AMD EPYC and 5th&nbsp;Gen Intel Xeon Scalable platforms across various configurations, workloads, and operating conditions.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44653936/broadcom-and-marvell-poised-for-growth-as-nvidias-cpo-push-faces-delays-analyst-reveals" rel="noreferrer noopener">Rising Tide Of AI Is So Strong That Semiconductor Optical Industry Projects $30 Billion Total Addressable Market By 2029</a>
The results demonstrated seamless interoperability, delivering stability, scalability, and high-performance memory expansion that cloud data center providers need for mass deployment.
The first-quarter&nbsp;<a target="_blank" href="https://www.benzinga.com/25/04/44852860/nvidia-lam-research-and-marvell-to-face-least-impact-from-tariffs-while-intel-and-arm-could-suffer-more-bofa-analyst'" rel="noreferrer noopener">semiconductor earnings procession</a> kicked off with&nbsp;ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) last Wednesday&nbsp;and Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) <a target="_blank" href="https://www.benzinga.com/25/04/44857887/taiwan-semiconductor-q1-surges-41-in-sales-boosted-by-ai-chip-demand-expanded-margins" rel="noreferrer noopener">on Thursday</a>.
For U.S. chip vendors,&nbsp;BofA Securities&nbsp;analysts Vivek Arya and Duksan Jang expect first-quarter results to beat as their original outlook was likely conservative and tariff-related pull-ins created a better demand environment. However, the second-quarter outlook could be in line as companies could widen the guidance range.
Marvell stock plunged over 55% year-to-date. Marvell&#8217;s <a target="_blank" href="https://www.benzinga.com/25/04/44683383/marvell-plays-ai-hardball-divestiture-sparks-155-upside-says-analyst" rel="noreferrer noopener">exit from the</a> auto space follows its October quarter restructuring, where it began shifting investments away from enterprise networking, carrier infrastructure, and automotive.
The company is now focused on AI and accelerated computing, a theme JPMorgan&#8217;s&nbsp;Harlan Sur sees as key to unlocking long-term value.
Price Action: MRVL stock closed higher by 6.22% to $53.77 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44903362/american-express-solid-revenue-and-spending-trends-drive-analyst-optimism" target="_blank" rel="noreferrer noopener">American Express&#8217; Solid Revenue, Spending Trends Drive Analyst Optimism</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

Movers

Tech

ASML

INTC

MRVL

What's Going On With Marvell Technology Stock On Wednesday?

Press Releases

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

Health Care

Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer ("SITC") 2024 Annual Meeting

Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment

Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024

Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy

Financing

Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Management

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

ELTX

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Agenus

Anixa Biosciences

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Atossa Therapeutics

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

Climb Bio

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Caribou Biosciences

CervoMed

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

IGM Biosciences

Invivyd

Seres Therapeutics

MediciNova

OncoCyte

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Tenaya Therapeutics

Vigil Neuroscience

Vor Biopharma

Vaxart

Whitehawk Therapeutics, Inc. - Common Stock

Comments

Elicio Therapeutics

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO